[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f63nUeXyuKYIsfuAm0_5xO7uFTLaif976RkjpIwRt4Js":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":35,"phaseBuckets":41,"rows":48},"Temple University",[4,6],"Temple University Collaborative on Community Inclusion",223,false,29,11,39946,1,172,[15,18,21,24,26,28,31,33],{"name":16,"count":17},"Obesity",18,{"name":19,"count":20},"Overweight",6,{"name":22,"count":23},"Chronic Obstructive Pulmonary Disease",5,{"name":25,"count":23},"Diabetes Mellitus",{"name":27,"count":23},"Hypertension",{"name":29,"count":30},"Diabetes",4,{"name":32,"count":30},"Anxiety",{"name":34,"count":30},"Gastroparesis",[36],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT05562349","Clavulanic Acid for the Treatment of Cocaine Use Disorder","2024-07","Clavulanic Acid Only Product",[42,43,44,45,46,47],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[49,72,113,137,162,189,207,231,256,281,299,324,350,376,394,419,447,465,491,515,540,565,591,615,639,663,689,715,778,824,860,882,921,943,965,983,1001,1019,1037,1055,1073,1091,1115,1139,1163,1181,1205,1229,1254,1279,1304,1330,1348,1398,1416,1442,1467,1489,1513,1531,1558,1587,1605,1623,1641,1659],{"intervention":40,"totalTrials":12,"cells":50},{"EARLY_PHASE1":51,"PHASE1":54,"PHASE2":56,"PHASE3":66,"PHASE4":68,"NA":70},{"trials":52,"activeCount":53},[],0,{"trials":55,"activeCount":53},[],{"trials":57,"activeCount":12,"soonestReadout":39},[58],{"nctId":37,"briefTitle":38,"status":59,"phases":60,"primaryCompletion":39,"completion":39,"start":61,"enrollment":62,"conditions":63,"interventions":65},"ACTIVE_NOT_RECRUITING",[44],"2023-05-03",65,[64],"Cocaine Dependence",[40],{"trials":67,"activeCount":53},[],{"trials":69,"activeCount":53},[],{"trials":71,"activeCount":53},[],{"intervention":73,"totalTrials":74,"cells":75},"Liraglutide",2,{"EARLY_PHASE1":76,"PHASE1":78,"PHASE2":80,"PHASE3":82,"PHASE4":84,"NA":111},{"trials":77,"activeCount":53},[],{"trials":79,"activeCount":53},[],{"trials":81,"activeCount":53},[],{"trials":83,"activeCount":53},[],{"trials":85,"activeCount":53},[86,98],{"nctId":87,"briefTitle":88,"status":89,"phases":90,"primaryCompletion":91,"completion":92,"start":93,"enrollment":94,"conditions":95,"interventions":97},"NCT02344186","Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes","UNKNOWN",[46],"2022-12-31","2023-12-31","2014-05",12,[96],"Type 2 Diabetes",[73],{"nctId":99,"briefTitle":100,"status":101,"phases":102,"primaryCompletion":103,"completion":104,"start":105,"enrollment":30,"conditions":106,"interventions":110},"NCT02743598","Liraglutide for HIV-associated Neurocognitive Disorder","TERMINATED",[46],"2018-06-01","2018-09","2016-09",[107,108,16,19,109],"HIV Infection","Diabetes Mellitus Type 2","Metabolic Syndrome",[73],{"trials":112,"activeCount":53},[],{"intervention":114,"totalTrials":12,"cells":115},"lopinavir\u002Fritonavir plus maraviroc",{"EARLY_PHASE1":116,"PHASE1":118,"PHASE2":120,"PHASE3":122,"PHASE4":124,"NA":135},{"trials":117,"activeCount":53},[],{"trials":119,"activeCount":53},[],{"trials":121,"activeCount":53},[],{"trials":123,"activeCount":53},[],{"trials":125,"activeCount":53},[126],{"nctId":127,"briefTitle":128,"status":101,"phases":129,"primaryCompletion":130,"completion":130,"start":131,"enrollment":12,"conditions":132,"interventions":134},"NCT01068873","Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)",[46],"2010-12","2010-04",[133],"HIV Infections",[114],{"trials":136,"activeCount":53},[],{"intervention":138,"totalTrials":12,"cells":139},"Metformin Therapy",{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":146,"PHASE4":148,"NA":160},{"trials":141,"activeCount":53},[],{"trials":143,"activeCount":53},[],{"trials":145,"activeCount":53},[],{"trials":147,"activeCount":53},[],{"trials":149,"activeCount":53},[150],{"nctId":151,"briefTitle":152,"status":153,"phases":154,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":158,"interventions":159},"NCT02088034","Intervention to Promote Weight Loss in Latinas At-risk for Diabetes","COMPLETED",[46],"2016-02","2013-09",92,[29],[138],{"trials":161,"activeCount":53},[],{"intervention":163,"totalTrials":12,"cells":164},"Triamcinolone",{"EARLY_PHASE1":165,"PHASE1":167,"PHASE2":169,"PHASE3":171,"PHASE4":173,"NA":187},{"trials":166,"activeCount":53},[],{"trials":168,"activeCount":53},[],{"trials":170,"activeCount":53},[],{"trials":172,"activeCount":53},[],{"trials":174,"activeCount":53},[175],{"nctId":176,"briefTitle":177,"status":178,"phases":179,"primaryCompletion":180,"start":181,"enrollment":53,"conditions":182,"interventions":185},"NCT02748395","Lidocaine and Triamcinolone vs Saline Trigger Point Injection for Treatment of Chronic Abdominal Wall Pain","WITHDRAWN",[46],"2016-12","2016-05",[183,184],"Chronic Abdominal Wall Pain","Abdominal Cutaneous Nerve Entrapment Syndrome",[163,186],"Lidocaine",{"trials":188,"activeCount":53},[],{"intervention":186,"totalTrials":12,"cells":190},{"EARLY_PHASE1":191,"PHASE1":193,"PHASE2":195,"PHASE3":197,"PHASE4":199,"NA":205},{"trials":192,"activeCount":53},[],{"trials":194,"activeCount":53},[],{"trials":196,"activeCount":53},[],{"trials":198,"activeCount":53},[],{"trials":200,"activeCount":53},[201],{"nctId":176,"briefTitle":177,"status":178,"phases":202,"primaryCompletion":180,"start":181,"enrollment":53,"conditions":203,"interventions":204},[46],[183,184],[163,186],{"trials":206,"activeCount":53},[],{"intervention":208,"totalTrials":12,"cells":209},"Omeprazole, Lansoprazole, Esomeprazole, Rantidine",{"EARLY_PHASE1":210,"PHASE1":212,"PHASE2":214,"PHASE3":216,"PHASE4":218,"NA":229},{"trials":211,"activeCount":53},[],{"trials":213,"activeCount":53},[],{"trials":215,"activeCount":53},[],{"trials":217,"activeCount":53},[],{"trials":219,"activeCount":53},[220],{"nctId":221,"briefTitle":222,"status":178,"phases":223,"primaryCompletion":224,"completion":225,"start":181,"enrollment":53,"conditions":226,"interventions":228},"NCT02530879","Comparison of Voice Therapy and Antireflex Therapy in LPR",[46],"2017-08","2018-01",[227],"Laryngopharyngeal Reflux",[208],{"trials":230,"activeCount":53},[],{"intervention":232,"totalTrials":12,"cells":233},"Lansoprazole",{"EARLY_PHASE1":234,"PHASE1":236,"PHASE2":238,"PHASE3":240,"PHASE4":242,"NA":254},{"trials":235,"activeCount":53},[],{"trials":237,"activeCount":53},[],{"trials":239,"activeCount":53},[],{"trials":241,"activeCount":53},[],{"trials":243,"activeCount":53},[244],{"nctId":245,"briefTitle":246,"status":101,"phases":247,"completion":248,"start":249,"enrollment":250,"conditions":251,"interventions":253},"NCT00220909","Lansoprazole Preventing Gastroduodenal Stress Ulcerations",[46],"2006-01","2005-09",40,[252],"Patients Undergoing Elective Coronary Artery Bypass Graft",[232],{"trials":255,"activeCount":53},[],{"intervention":257,"totalTrials":12,"cells":258},"PEG-3350 and Gatorade",{"EARLY_PHASE1":259,"PHASE1":261,"PHASE2":263,"PHASE3":265,"PHASE4":267,"NA":279},{"trials":260,"activeCount":53},[],{"trials":262,"activeCount":53},[],{"trials":264,"activeCount":53},[],{"trials":266,"activeCount":53},[],{"trials":268,"activeCount":53},[269],{"nctId":270,"briefTitle":271,"status":153,"phases":272,"primaryCompletion":273,"completion":273,"start":131,"enrollment":274,"conditions":275,"interventions":277},"NCT01170754","Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy",[46],"2011-07",136,[276],"Colon Cancer",[257,278],"Golytely 4 liters",{"trials":280,"activeCount":53},[],{"intervention":278,"totalTrials":12,"cells":282},{"EARLY_PHASE1":283,"PHASE1":285,"PHASE2":287,"PHASE3":289,"PHASE4":291,"NA":297},{"trials":284,"activeCount":53},[],{"trials":286,"activeCount":53},[],{"trials":288,"activeCount":53},[],{"trials":290,"activeCount":53},[],{"trials":292,"activeCount":53},[293],{"nctId":270,"briefTitle":271,"status":153,"phases":294,"primaryCompletion":273,"completion":273,"start":131,"enrollment":274,"conditions":295,"interventions":296},[46],[276],[257,278],{"trials":298,"activeCount":53},[],{"intervention":300,"totalTrials":12,"cells":301},"Dronabinol",{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":306,"PHASE3":308,"PHASE4":310,"NA":322},{"trials":303,"activeCount":53},[],{"trials":305,"activeCount":53},[],{"trials":307,"activeCount":53},[],{"trials":309,"activeCount":53},[],{"trials":311,"activeCount":53},[312],{"nctId":313,"briefTitle":314,"status":178,"phases":315,"primaryCompletion":316,"completion":317,"start":318,"enrollment":53,"conditions":319,"interventions":321},"NCT02569073","Investigation of Cannabinoid Receptor Agonist Dronabinol in Patients With Functional Chest Pain",[46],"2019-08-01","2019-09-01","2017-06-21",[320],"Esophageal Diseases",[300],{"trials":323,"activeCount":53},[],{"intervention":325,"totalTrials":12,"cells":326},"Tacrolimus Extended Release Oral Tablet [Envarsus] 0.13mg\u002Fkg\u002Fday initiated within post-operative day 3 after kidney transplant",{"EARLY_PHASE1":327,"PHASE1":329,"PHASE2":331,"PHASE3":333,"PHASE4":335,"NA":348},{"trials":328,"activeCount":53},[],{"trials":330,"activeCount":53},[],{"trials":332,"activeCount":53},[],{"trials":334,"activeCount":53},[],{"trials":336,"activeCount":53},[337],{"nctId":338,"briefTitle":339,"status":153,"phases":340,"primaryCompletion":341,"completion":342,"start":343,"enrollment":344,"conditions":345,"interventions":347},"NCT03713645","Dosing Strategies for de Novo Once-daily Extended Release Tacrolimus (LCPT) in Kidney Transplant Recipients",[46],"2021-05-23","2022-01-31","2018-11-12",36,[346],"Kidney Transplant",[325],{"trials":349,"activeCount":53},[],{"intervention":351,"totalTrials":12,"cells":352},"neostigmine\u002Fglycopyrrolate",{"EARLY_PHASE1":353,"PHASE1":355,"PHASE2":357,"PHASE3":359,"PHASE4":361,"NA":374},{"trials":354,"activeCount":53},[],{"trials":356,"activeCount":53},[],{"trials":358,"activeCount":53},[],{"trials":360,"activeCount":53},[],{"trials":362,"activeCount":53},[363],{"nctId":364,"briefTitle":365,"status":153,"phases":366,"primaryCompletion":367,"completion":367,"start":368,"enrollment":369,"conditions":370,"interventions":372},"NCT04606901","Comparison of Time to Extubation Using Sugammadex or Neostigmine",[46],"2023-07-30","2021-04-08",58,[371,22],"Neuromuscular Blockade",[351,373],"sugammadex",{"trials":375,"activeCount":53},[],{"intervention":373,"totalTrials":12,"cells":377},{"EARLY_PHASE1":378,"PHASE1":380,"PHASE2":382,"PHASE3":384,"PHASE4":386,"NA":392},{"trials":379,"activeCount":53},[],{"trials":381,"activeCount":53},[],{"trials":383,"activeCount":53},[],{"trials":385,"activeCount":53},[],{"trials":387,"activeCount":53},[388],{"nctId":364,"briefTitle":365,"status":153,"phases":389,"primaryCompletion":367,"completion":367,"start":368,"enrollment":369,"conditions":390,"interventions":391},[46],[371,22],[351,373],{"trials":393,"activeCount":53},[],{"intervention":395,"totalTrials":12,"cells":396},"Insulin",{"EARLY_PHASE1":397,"PHASE1":399,"PHASE2":401,"PHASE3":403,"PHASE4":405,"NA":417},{"trials":398,"activeCount":53},[],{"trials":400,"activeCount":53},[],{"trials":402,"activeCount":53},[],{"trials":404,"activeCount":53},[],{"trials":406,"activeCount":53},[407],{"nctId":408,"briefTitle":409,"status":153,"phases":410,"primaryCompletion":411,"completion":411,"start":412,"enrollment":413,"conditions":414,"interventions":416},"NCT00779701","Strict Glycemic Control by Insulin Infusion:Observations on Emergency Department Initiation",[46],"2009-10","2007-03",27,[415],"Hyperglycemia",[395],{"trials":418,"activeCount":53},[],{"intervention":420,"totalTrials":12,"cells":421},"Dexmedetomidine",{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":426,"PHASE3":428,"PHASE4":430,"NA":445},{"trials":423,"activeCount":53},[],{"trials":425,"activeCount":53},[],{"trials":427,"activeCount":53},[],{"trials":429,"activeCount":53},[],{"trials":431,"activeCount":53},[432],{"nctId":433,"briefTitle":434,"status":89,"phases":435,"primaryCompletion":436,"completion":436,"start":437,"enrollment":438,"conditions":439,"interventions":443},"NCT06093451","Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder",[46],"2024-07-01","2023-07-01",32,[440,441,442,420],"Schizophrenia Agitation","Schizo Affective Disorder","Bipolar Disorder",[420,444],"Lorazepam 2 MG\u002FML",{"trials":446,"activeCount":53},[],{"intervention":444,"totalTrials":12,"cells":448},{"EARLY_PHASE1":449,"PHASE1":451,"PHASE2":453,"PHASE3":455,"PHASE4":457,"NA":463},{"trials":450,"activeCount":53},[],{"trials":452,"activeCount":53},[],{"trials":454,"activeCount":53},[],{"trials":456,"activeCount":53},[],{"trials":458,"activeCount":53},[459],{"nctId":433,"briefTitle":434,"status":89,"phases":460,"primaryCompletion":436,"completion":436,"start":437,"enrollment":438,"conditions":461,"interventions":462},[46],[440,441,442,420],[420,444],{"trials":464,"activeCount":53},[],{"intervention":466,"totalTrials":12,"cells":467},"sirolimus",{"EARLY_PHASE1":468,"PHASE1":470,"PHASE2":472,"PHASE3":474,"PHASE4":476,"NA":489},{"trials":469,"activeCount":53},[],{"trials":471,"activeCount":53},[],{"trials":473,"activeCount":53},[],{"trials":475,"activeCount":53},[],{"trials":477,"activeCount":53},[478],{"nctId":479,"briefTitle":480,"status":89,"phases":481,"primaryCompletion":482,"completion":482,"start":483,"enrollment":484,"conditions":485,"interventions":488},"NCT00999258","Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients",[46],"2011-06","2009-09",50,[486,487],"Glomerular Filtration Rate","Chronic Allograft Nephropathy",[466],{"trials":490,"activeCount":53},[],{"intervention":492,"totalTrials":12,"cells":493},"Rabeprazole",{"EARLY_PHASE1":494,"PHASE1":496,"PHASE2":498,"PHASE3":500,"PHASE4":502,"NA":513},{"trials":495,"activeCount":53},[],{"trials":497,"activeCount":53},[],{"trials":499,"activeCount":53},[],{"trials":501,"activeCount":53},[],{"trials":503,"activeCount":53},[504],{"nctId":505,"briefTitle":506,"status":153,"phases":507,"primaryCompletion":508,"completion":508,"start":249,"enrollment":509,"conditions":510,"interventions":512},"NCT00220857","Rabeprazole Protection of Aspirin Induced Gastric Damage.",[46],"2007-09",30,[511],"Normal Subjects",[492],{"trials":514,"activeCount":53},[],{"intervention":516,"totalTrials":12,"cells":517},"Paroxetine",{"EARLY_PHASE1":518,"PHASE1":520,"PHASE2":522,"PHASE3":524,"PHASE4":536,"NA":538},{"trials":519,"activeCount":53},[],{"trials":521,"activeCount":53},[],{"trials":523,"activeCount":53},[],{"trials":525,"activeCount":53},[526],{"nctId":527,"briefTitle":528,"status":153,"phases":529,"primaryCompletion":530,"completion":530,"start":531,"enrollment":532,"conditions":533,"interventions":535},"NCT00074802","Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder",[45],"2008-05","2003-12",150,[534],"Social Anxiety Disorder",[516],{"trials":537,"activeCount":53},[],{"trials":539,"activeCount":53},[],{"intervention":541,"totalTrials":12,"cells":542},"methylphenidate",{"EARLY_PHASE1":543,"PHASE1":545,"PHASE2":547,"PHASE3":549,"PHASE4":561,"NA":563},{"trials":544,"activeCount":53},[],{"trials":546,"activeCount":53},[],{"trials":548,"activeCount":53},[],{"trials":550,"activeCount":53},[551],{"nctId":552,"briefTitle":553,"status":153,"phases":554,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":558,"interventions":560},"NCT01411280","Ameliorating Attention Problems in Children With Sickle Cell Disease (SCD)",[45],"2009-05","2006-06",34,[559],"Sickle Cell Disease",[541],{"trials":562,"activeCount":53},[],{"trials":564,"activeCount":53},[],{"intervention":566,"totalTrials":12,"cells":567},"Budesonide\u002Fformoterol",{"EARLY_PHASE1":568,"PHASE1":570,"PHASE2":572,"PHASE3":574,"PHASE4":587,"NA":589},{"trials":569,"activeCount":53},[],{"trials":571,"activeCount":53},[],{"trials":573,"activeCount":53},[],{"trials":575,"activeCount":53},[576],{"nctId":577,"briefTitle":578,"status":89,"phases":579,"primaryCompletion":580,"completion":581,"start":582,"enrollment":250,"conditions":583,"interventions":586},"NCT01602523","Effect of Symbicort on Sleep Quality in Patients With Emphysema",[45],"2014-04","2014-08","2011-03",[584,585],"Emphysema","Poor Sleep Quality",[566],{"trials":588,"activeCount":53},[],{"trials":590,"activeCount":53},[],{"intervention":592,"totalTrials":12,"cells":593},"Ivermectin Pill",{"EARLY_PHASE1":594,"PHASE1":596,"PHASE2":598,"PHASE3":600,"PHASE4":611,"NA":613},{"trials":595,"activeCount":53},[],{"trials":597,"activeCount":53},[],{"trials":599,"activeCount":53},[],{"trials":601,"activeCount":53},[602],{"nctId":603,"briefTitle":604,"status":178,"phases":605,"primaryCompletion":606,"completion":606,"start":607,"enrollment":53,"conditions":608,"interventions":610},"NCT04530474","Outpatient Use of Ivermectin in COVID-19",[45],"2021-06-30","2021-04-01",[609],"Covid19",[592],{"trials":612,"activeCount":53},[],{"trials":614,"activeCount":53},[],{"intervention":616,"totalTrials":12,"cells":617},"Atomoxetine",{"EARLY_PHASE1":618,"PHASE1":620,"PHASE2":622,"PHASE3":624,"PHASE4":635,"NA":637},{"trials":619,"activeCount":53},[],{"trials":621,"activeCount":53},[],{"trials":623,"activeCount":53},[],{"trials":625,"activeCount":53},[626],{"nctId":627,"briefTitle":628,"status":178,"phases":629,"start":630,"enrollment":53,"conditions":631,"interventions":634},"NCT00255138","Efficacy of Atomoxetine Therapy Versus Placebo for Cognitive Late Effects",[45],"2005-11",[632,633],"Cancer","Cognitive Late Effects",[616],{"trials":636,"activeCount":53},[],{"trials":638,"activeCount":53},[],{"intervention":640,"totalTrials":12,"cells":641},"Sancuso®",{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":648,"PHASE4":659,"NA":661},{"trials":643,"activeCount":53},[],{"trials":645,"activeCount":53},[],{"trials":647,"activeCount":53},[],{"trials":649,"activeCount":53},[650],{"nctId":651,"briefTitle":652,"status":153,"phases":653,"primaryCompletion":654,"completion":654,"start":655,"enrollment":656,"conditions":657,"interventions":658},"NCT01989221","Sancuso® for Gastroparesis: An Open Label Study.",[45],"2018-12","2012-11",14,[34],[640],{"trials":660,"activeCount":53},[],{"trials":662,"activeCount":53},[],{"intervention":664,"totalTrials":12,"cells":665},"Roflumilast",{"EARLY_PHASE1":666,"PHASE1":668,"PHASE2":670,"PHASE3":672,"PHASE4":685,"NA":687},{"trials":667,"activeCount":53},[],{"trials":669,"activeCount":53},[],{"trials":671,"activeCount":53},[],{"trials":673,"activeCount":53},[674],{"nctId":675,"briefTitle":676,"status":153,"phases":677,"primaryCompletion":678,"completion":679,"start":680,"enrollment":681,"conditions":682,"interventions":684},"NCT01973998","Effects of Roflumilast in Hospitalized Chronic Obstructive Pulmonary Disease( COPD) on Mortality and Re-hospitalization",[45],"2017-11-10","2017-11-30","2013-11",68,[683],"COPD",[664],{"trials":686,"activeCount":53},[],{"trials":688,"activeCount":53},[],{"intervention":690,"totalTrials":12,"cells":691},"Eluxadoline 100 mg",{"EARLY_PHASE1":692,"PHASE1":694,"PHASE2":696,"PHASE3":698,"PHASE4":711,"NA":713},{"trials":693,"activeCount":53},[],{"trials":695,"activeCount":53},[],{"trials":697,"activeCount":53},[],{"trials":699,"activeCount":53},[700],{"nctId":701,"briefTitle":702,"status":178,"phases":703,"primaryCompletion":704,"completion":705,"start":706,"enrollment":53,"conditions":707,"interventions":710},"NCT04313088","Investigation of Eluxadoline for Diabetic Diarrhea",[44,45],"2023-12","2024-12","2022-07-01",[708,29,709],"Diabetic Diarrhea","Diarrhea",[690],{"trials":712,"activeCount":53},[],{"trials":714,"activeCount":53},[],{"intervention":716,"totalTrials":23,"cells":717},"etoposide",{"EARLY_PHASE1":718,"PHASE1":720,"PHASE2":722,"PHASE3":772,"PHASE4":774,"NA":776},{"trials":719,"activeCount":53},[],{"trials":721,"activeCount":53},[],{"trials":723,"activeCount":53},[724,736,748,757,765],{"nctId":725,"briefTitle":726,"status":153,"phases":727,"primaryCompletion":728,"completion":728,"start":729,"conditions":730,"interventions":734},"NCT00002508","Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors",[43,44],"2001-09","1990-11",[731,732,733],"Extragonadal Germ Cell Tumor","Ovarian Cancer","Testicular Germ Cell Tumor",[735,716],"carboplatin",{"nctId":737,"briefTitle":738,"status":153,"phases":739,"primaryCompletion":740,"completion":740,"start":741,"conditions":742,"interventions":744},"NCT00002510","Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma",[43,44],"2001-06","1992-04",[743],"Lymphoma",[745,746,716,747],"filgrastim","cyclophosphamide","mesna",{"nctId":749,"briefTitle":750,"status":153,"phases":751,"primaryCompletion":752,"completion":752,"start":753,"conditions":754,"interventions":755},"NCT00002522","Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma",[44],"2002-02","1993-02",[743],[756,746,716],"cisplatin",{"nctId":758,"briefTitle":759,"status":153,"phases":760,"primaryCompletion":531,"completion":531,"start":761,"conditions":762,"interventions":764},"NCT00002509","High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer",[43,44],"1991-11",[763],"Breast Cancer",[745,735,746,716,747],{"nctId":766,"briefTitle":767,"status":153,"phases":768,"primaryCompletion":769,"completion":769,"start":753,"conditions":770,"interventions":771},"NCT00002521","Combination Chemotherapy and Bone Marrow and\u002For Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma",[44],"2000-02",[743],[756,746,716],{"trials":773,"activeCount":53},[],{"trials":775,"activeCount":53},[],{"trials":777,"activeCount":53},[],{"intervention":746,"totalTrials":23,"cells":779},{"EARLY_PHASE1":780,"PHASE1":782,"PHASE2":784,"PHASE3":818,"PHASE4":820,"NA":822},{"trials":781,"activeCount":53},[],{"trials":783,"activeCount":53},[],{"trials":785,"activeCount":53},[786,790,794,798,814],{"nctId":737,"briefTitle":738,"status":153,"phases":787,"primaryCompletion":740,"completion":740,"start":741,"conditions":788,"interventions":789},[43,44],[743],[745,746,716,747],{"nctId":749,"briefTitle":750,"status":153,"phases":791,"primaryCompletion":752,"completion":752,"start":753,"conditions":792,"interventions":793},[44],[743],[756,746,716],{"nctId":758,"briefTitle":759,"status":153,"phases":795,"primaryCompletion":531,"completion":531,"start":761,"conditions":796,"interventions":797},[43,44],[763],[745,735,746,716,747],{"nctId":799,"briefTitle":800,"status":153,"phases":801,"primaryCompletion":531,"completion":531,"start":802,"enrollment":803,"conditions":804,"interventions":808},"NCT00002809","Bone Marrow Transplant Plus Cyclophosphamide and Total-Body Irradiation in Treating Patients With Hematologic Cancer",[44],"1996-08",10,[805,806,807],"Leukemia","Myelodysplastic Syndromes","Myelodysplastic\u002FMyeloproliferative Diseases",[809,745,810,811,746,812,813],"anti-thymocyte globulin","sargramostim","therapeutic immune globulin","methotrexate","tacrolimus",{"nctId":766,"briefTitle":767,"status":153,"phases":815,"primaryCompletion":769,"completion":769,"start":753,"conditions":816,"interventions":817},[44],[743],[756,746,716],{"trials":819,"activeCount":53},[],{"trials":821,"activeCount":53},[],{"trials":823,"activeCount":53},[],{"intervention":745,"totalTrials":30,"cells":825},{"EARLY_PHASE1":826,"PHASE1":828,"PHASE2":830,"PHASE3":854,"PHASE4":856,"NA":858},{"trials":827,"activeCount":53},[],{"trials":829,"activeCount":53},[],{"trials":831,"activeCount":53},[832,836,840,850],{"nctId":737,"briefTitle":738,"status":153,"phases":833,"primaryCompletion":740,"completion":740,"start":741,"conditions":834,"interventions":835},[43,44],[743],[745,746,716,747],{"nctId":758,"briefTitle":759,"status":153,"phases":837,"primaryCompletion":531,"completion":531,"start":761,"conditions":838,"interventions":839},[43,44],[763],[745,735,746,716,747],{"nctId":841,"briefTitle":842,"status":153,"phases":843,"primaryCompletion":844,"completion":844,"start":845,"conditions":846,"interventions":848},"NCT00002810","High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis",[44],"2006-05","1996-05",[847],"Multiple Myeloma and Plasma Cell Neoplasm",[745,849],"melphalan",{"nctId":799,"briefTitle":800,"status":153,"phases":851,"primaryCompletion":531,"completion":531,"start":802,"enrollment":803,"conditions":852,"interventions":853},[44],[805,806,807],[809,745,810,811,746,812,813],{"trials":855,"activeCount":53},[],{"trials":857,"activeCount":53},[],{"trials":859,"activeCount":53},[],{"intervention":735,"totalTrials":74,"cells":861},{"EARLY_PHASE1":862,"PHASE1":864,"PHASE2":866,"PHASE3":876,"PHASE4":878,"NA":880},{"trials":863,"activeCount":53},[],{"trials":865,"activeCount":53},[],{"trials":867,"activeCount":53},[868,872],{"nctId":725,"briefTitle":726,"status":153,"phases":869,"primaryCompletion":728,"completion":728,"start":729,"conditions":870,"interventions":871},[43,44],[731,732,733],[735,716],{"nctId":758,"briefTitle":759,"status":153,"phases":873,"primaryCompletion":531,"completion":531,"start":761,"conditions":874,"interventions":875},[43,44],[763],[745,735,746,716,747],{"trials":877,"activeCount":53},[],{"trials":879,"activeCount":53},[],{"trials":881,"activeCount":53},[],{"intervention":883,"totalTrials":74,"cells":884},"Saline",{"EARLY_PHASE1":885,"PHASE1":887,"PHASE2":889,"PHASE3":915,"PHASE4":917,"NA":919},{"trials":886,"activeCount":53},[],{"trials":888,"activeCount":53},[],{"trials":890,"activeCount":53},[891,902],{"nctId":892,"briefTitle":893,"status":153,"phases":894,"primaryCompletion":895,"completion":896,"start":155,"enrollment":897,"conditions":898,"interventions":900},"NCT02639052","Itch Relieving Effect of Botox: a Study in Healthy Subjects",[43,44],"2016-07","2017-01",35,[899],"Pruritus",[901,883],"Botox",{"nctId":903,"briefTitle":904,"status":153,"phases":905,"primaryCompletion":906,"completion":907,"start":908,"enrollment":909,"conditions":910,"interventions":913},"NCT04919317","Combination Dexamethasone and Bupivacaine Pain Control in Reduction Mammaplasty",[44],"2020-11-07","2020-11-25","2017-09-29",56,[911,912],"Pain, Postoperative","Mammaplasty",[914,883],"Dexamethasone 4mg",{"trials":916,"activeCount":53},[],{"trials":918,"activeCount":53},[],{"trials":920,"activeCount":53},[],{"intervention":747,"totalTrials":74,"cells":922},{"EARLY_PHASE1":923,"PHASE1":925,"PHASE2":927,"PHASE3":937,"PHASE4":939,"NA":941},{"trials":924,"activeCount":53},[],{"trials":926,"activeCount":53},[],{"trials":928,"activeCount":53},[929,933],{"nctId":737,"briefTitle":738,"status":153,"phases":930,"primaryCompletion":740,"completion":740,"start":741,"conditions":931,"interventions":932},[43,44],[743],[745,746,716,747],{"nctId":758,"briefTitle":759,"status":153,"phases":934,"primaryCompletion":531,"completion":531,"start":761,"conditions":935,"interventions":936},[43,44],[763],[745,735,746,716,747],{"trials":938,"activeCount":53},[],{"trials":940,"activeCount":53},[],{"trials":942,"activeCount":53},[],{"intervention":756,"totalTrials":74,"cells":944},{"EARLY_PHASE1":945,"PHASE1":947,"PHASE2":949,"PHASE3":959,"PHASE4":961,"NA":963},{"trials":946,"activeCount":53},[],{"trials":948,"activeCount":53},[],{"trials":950,"activeCount":53},[951,955],{"nctId":749,"briefTitle":750,"status":153,"phases":952,"primaryCompletion":752,"completion":752,"start":753,"conditions":953,"interventions":954},[44],[743],[756,746,716],{"nctId":766,"briefTitle":767,"status":153,"phases":956,"primaryCompletion":769,"completion":769,"start":753,"conditions":957,"interventions":958},[44],[743],[756,746,716],{"trials":960,"activeCount":53},[],{"trials":962,"activeCount":53},[],{"trials":964,"activeCount":53},[],{"intervention":901,"totalTrials":12,"cells":966},{"EARLY_PHASE1":967,"PHASE1":969,"PHASE2":971,"PHASE3":977,"PHASE4":979,"NA":981},{"trials":968,"activeCount":53},[],{"trials":970,"activeCount":53},[],{"trials":972,"activeCount":53},[973],{"nctId":892,"briefTitle":893,"status":153,"phases":974,"primaryCompletion":895,"completion":896,"start":155,"enrollment":897,"conditions":975,"interventions":976},[43,44],[899],[901,883],{"trials":978,"activeCount":53},[],{"trials":980,"activeCount":53},[],{"trials":982,"activeCount":53},[],{"intervention":849,"totalTrials":12,"cells":984},{"EARLY_PHASE1":985,"PHASE1":987,"PHASE2":989,"PHASE3":995,"PHASE4":997,"NA":999},{"trials":986,"activeCount":53},[],{"trials":988,"activeCount":53},[],{"trials":990,"activeCount":53},[991],{"nctId":841,"briefTitle":842,"status":153,"phases":992,"primaryCompletion":844,"completion":844,"start":845,"conditions":993,"interventions":994},[44],[847],[745,849],{"trials":996,"activeCount":53},[],{"trials":998,"activeCount":53},[],{"trials":1000,"activeCount":53},[],{"intervention":809,"totalTrials":12,"cells":1002},{"EARLY_PHASE1":1003,"PHASE1":1005,"PHASE2":1007,"PHASE3":1013,"PHASE4":1015,"NA":1017},{"trials":1004,"activeCount":53},[],{"trials":1006,"activeCount":53},[],{"trials":1008,"activeCount":53},[1009],{"nctId":799,"briefTitle":800,"status":153,"phases":1010,"primaryCompletion":531,"completion":531,"start":802,"enrollment":803,"conditions":1011,"interventions":1012},[44],[805,806,807],[809,745,810,811,746,812,813],{"trials":1014,"activeCount":53},[],{"trials":1016,"activeCount":53},[],{"trials":1018,"activeCount":53},[],{"intervention":810,"totalTrials":12,"cells":1020},{"EARLY_PHASE1":1021,"PHASE1":1023,"PHASE2":1025,"PHASE3":1031,"PHASE4":1033,"NA":1035},{"trials":1022,"activeCount":53},[],{"trials":1024,"activeCount":53},[],{"trials":1026,"activeCount":53},[1027],{"nctId":799,"briefTitle":800,"status":153,"phases":1028,"primaryCompletion":531,"completion":531,"start":802,"enrollment":803,"conditions":1029,"interventions":1030},[44],[805,806,807],[809,745,810,811,746,812,813],{"trials":1032,"activeCount":53},[],{"trials":1034,"activeCount":53},[],{"trials":1036,"activeCount":53},[],{"intervention":811,"totalTrials":12,"cells":1038},{"EARLY_PHASE1":1039,"PHASE1":1041,"PHASE2":1043,"PHASE3":1049,"PHASE4":1051,"NA":1053},{"trials":1040,"activeCount":53},[],{"trials":1042,"activeCount":53},[],{"trials":1044,"activeCount":53},[1045],{"nctId":799,"briefTitle":800,"status":153,"phases":1046,"primaryCompletion":531,"completion":531,"start":802,"enrollment":803,"conditions":1047,"interventions":1048},[44],[805,806,807],[809,745,810,811,746,812,813],{"trials":1050,"activeCount":53},[],{"trials":1052,"activeCount":53},[],{"trials":1054,"activeCount":53},[],{"intervention":812,"totalTrials":12,"cells":1056},{"EARLY_PHASE1":1057,"PHASE1":1059,"PHASE2":1061,"PHASE3":1067,"PHASE4":1069,"NA":1071},{"trials":1058,"activeCount":53},[],{"trials":1060,"activeCount":53},[],{"trials":1062,"activeCount":53},[1063],{"nctId":799,"briefTitle":800,"status":153,"phases":1064,"primaryCompletion":531,"completion":531,"start":802,"enrollment":803,"conditions":1065,"interventions":1066},[44],[805,806,807],[809,745,810,811,746,812,813],{"trials":1068,"activeCount":53},[],{"trials":1070,"activeCount":53},[],{"trials":1072,"activeCount":53},[],{"intervention":813,"totalTrials":12,"cells":1074},{"EARLY_PHASE1":1075,"PHASE1":1077,"PHASE2":1079,"PHASE3":1085,"PHASE4":1087,"NA":1089},{"trials":1076,"activeCount":53},[],{"trials":1078,"activeCount":53},[],{"trials":1080,"activeCount":53},[1081],{"nctId":799,"briefTitle":800,"status":153,"phases":1082,"primaryCompletion":531,"completion":531,"start":802,"enrollment":803,"conditions":1083,"interventions":1084},[44],[805,806,807],[809,745,810,811,746,812,813],{"trials":1086,"activeCount":53},[],{"trials":1088,"activeCount":53},[],{"trials":1090,"activeCount":53},[],{"intervention":1092,"totalTrials":12,"cells":1093},"Mepolizumab 100 MG",{"EARLY_PHASE1":1094,"PHASE1":1096,"PHASE2":1098,"PHASE3":1109,"PHASE4":1111,"NA":1113},{"trials":1095,"activeCount":53},[],{"trials":1097,"activeCount":53},[],{"trials":1099,"activeCount":53},[1100],{"nctId":1101,"briefTitle":1102,"status":89,"phases":1103,"primaryCompletion":1104,"completion":1105,"start":1106,"enrollment":509,"conditions":1107,"interventions":1108},"NCT05320939","Immunological Basis for Mepolizumab Activity in COPD",[44],"2024-04","2025-05","2023-04",[683],[1092],{"trials":1110,"activeCount":53},[],{"trials":1112,"activeCount":53},[],{"trials":1114,"activeCount":53},[],{"intervention":1116,"totalTrials":12,"cells":1117},"99mTc-rBitistatin",{"EARLY_PHASE1":1118,"PHASE1":1120,"PHASE2":1122,"PHASE3":1133,"PHASE4":1135,"NA":1137},{"trials":1119,"activeCount":53},[],{"trials":1121,"activeCount":53},[],{"trials":1123,"activeCount":53},[1124],{"nctId":1125,"briefTitle":1126,"status":178,"phases":1127,"primaryCompletion":1128,"completion":1128,"start":1129,"enrollment":53,"conditions":1130,"interventions":1132},"NCT00808626","Phase II Investigation of 99mTc-rBitistatin for Imaging Venous Thrombosis",[43,44],"2017-03","2008-12",[1131],"Venous Thrombosis",[1116],{"trials":1134,"activeCount":53},[],{"trials":1136,"activeCount":53},[],{"trials":1138,"activeCount":53},[],{"intervention":1140,"totalTrials":12,"cells":1141},"Naloxegol 25 MG Oral Tablet [Movantik]",{"EARLY_PHASE1":1142,"PHASE1":1144,"PHASE2":1146,"PHASE3":1157,"PHASE4":1159,"NA":1161},{"trials":1143,"activeCount":53},[],{"trials":1145,"activeCount":53},[],{"trials":1147,"activeCount":53},[1148],{"nctId":1149,"briefTitle":1150,"status":178,"phases":1151,"primaryCompletion":1152,"completion":1152,"start":1153,"enrollment":53,"conditions":1154,"interventions":1156},"NCT03036891","Naloxegol for Opioid-Related Gastroparesis",[44],"2019-09-30","2016-12-29",[34,1155],"Opioid Use",[1140],{"trials":1158,"activeCount":53},[],{"trials":1160,"activeCount":53},[],{"trials":1162,"activeCount":53},[],{"intervention":914,"totalTrials":12,"cells":1164},{"EARLY_PHASE1":1165,"PHASE1":1167,"PHASE2":1169,"PHASE3":1175,"PHASE4":1177,"NA":1179},{"trials":1166,"activeCount":53},[],{"trials":1168,"activeCount":53},[],{"trials":1170,"activeCount":53},[1171],{"nctId":903,"briefTitle":904,"status":153,"phases":1172,"primaryCompletion":906,"completion":907,"start":908,"enrollment":909,"conditions":1173,"interventions":1174},[44],[911,912],[914,883],{"trials":1176,"activeCount":53},[],{"trials":1178,"activeCount":53},[],{"trials":1180,"activeCount":53},[],{"intervention":1182,"totalTrials":12,"cells":1183},"Naloxegol",{"EARLY_PHASE1":1184,"PHASE1":1186,"PHASE2":1188,"PHASE3":1199,"PHASE4":1201,"NA":1203},{"trials":1185,"activeCount":53},[],{"trials":1187,"activeCount":53},[],{"trials":1189,"activeCount":53},[1190],{"nctId":1191,"briefTitle":1192,"status":101,"phases":1193,"primaryCompletion":1194,"completion":1194,"start":896,"enrollment":74,"conditions":1195,"interventions":1198},"NCT02998606","Movantik for Opioid-Related Esophageal Disorders",[44],"2018-10",[1196,1197],"Opioid-Induced Disorders","Esophagus Disorder",[1182],{"trials":1200,"activeCount":53},[],{"trials":1202,"activeCount":53},[],{"trials":1204,"activeCount":53},[],{"intervention":1206,"totalTrials":12,"cells":1207},"Quercetin",{"EARLY_PHASE1":1208,"PHASE1":1210,"PHASE2":1212,"PHASE3":1223,"PHASE4":1225,"NA":1227},{"trials":1209,"activeCount":53},[],{"trials":1211,"activeCount":53},[],{"trials":1213,"activeCount":53},[1214],{"nctId":1215,"briefTitle":1216,"status":89,"phases":1217,"primaryCompletion":1218,"completion":1219,"start":1220,"enrollment":9,"conditions":1221,"interventions":1222},"NCT03989271","Biological Effects of Quercetin in COPD",[43,44],"2024-05-30","2025-07-01","2019-10-01",[22],[1206],{"trials":1224,"activeCount":53},[],{"trials":1226,"activeCount":53},[],{"trials":1228,"activeCount":53},[],{"intervention":1230,"totalTrials":12,"cells":1231},"Benralizumab",{"EARLY_PHASE1":1232,"PHASE1":1234,"PHASE2":1236,"PHASE3":1248,"PHASE4":1250,"NA":1252},{"trials":1233,"activeCount":53},[],{"trials":1235,"activeCount":53},[],{"trials":1237,"activeCount":53},[1238],{"nctId":1239,"briefTitle":1240,"status":89,"phases":1241,"primaryCompletion":1242,"completion":1243,"start":1106,"enrollment":1244,"conditions":1245,"interventions":1247},"NCT05273359","Immunological Basis for Benralizumab Activity in Chronic Obstructive Pulmonary Disease (COPD)",[44],"2024-06","2025-01",45,[1246],"Chronic Obstructive Pulmonary Disease (COPD)",[1230],{"trials":1249,"activeCount":53},[],{"trials":1251,"activeCount":53},[],{"trials":1253,"activeCount":53},[],{"intervention":1255,"totalTrials":12,"cells":1256},"Doxycycline",{"EARLY_PHASE1":1257,"PHASE1":1259,"PHASE2":1261,"PHASE3":1273,"PHASE4":1275,"NA":1277},{"trials":1258,"activeCount":53},[],{"trials":1260,"activeCount":53},[],{"trials":1262,"activeCount":53},[1263],{"nctId":1264,"briefTitle":1265,"status":178,"phases":1266,"primaryCompletion":1267,"completion":1267,"start":1268,"enrollment":53,"conditions":1269,"interventions":1272},"NCT04433078","RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM",[44],"2021-04-13","2020-06-22",[1270,1271],"Cytokine Storm","SARS-CoV-2",[1255],{"trials":1274,"activeCount":53},[],{"trials":1276,"activeCount":53},[],{"trials":1278,"activeCount":53},[],{"intervention":1280,"totalTrials":12,"cells":1281},"Nintedanib",{"EARLY_PHASE1":1282,"PHASE1":1284,"PHASE2":1286,"PHASE3":1298,"PHASE4":1300,"NA":1302},{"trials":1283,"activeCount":53},[],{"trials":1285,"activeCount":53},[],{"trials":1287,"activeCount":53},[1288],{"nctId":1289,"briefTitle":1290,"status":101,"phases":1291,"primaryCompletion":1292,"completion":1292,"start":1293,"enrollment":12,"conditions":1294,"interventions":1297},"NCT03562416","Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects",[44],"2021-12-21","2019-07-05",[1295,1296],"Idiopathic Pulmonary Fibrosis","Lung Transplant; Complications",[1280],{"trials":1299,"activeCount":53},[],{"trials":1301,"activeCount":53},[],{"trials":1303,"activeCount":53},[],{"intervention":1305,"totalTrials":12,"cells":1306},"Quercetin 1000 mg",{"EARLY_PHASE1":1307,"PHASE1":1309,"PHASE2":1311,"PHASE3":1324,"PHASE4":1326,"NA":1328},{"trials":1308,"activeCount":53},[],{"trials":1310,"activeCount":53},[],{"trials":1312,"activeCount":53},[1313],{"nctId":1314,"briefTitle":1315,"status":89,"phases":1316,"primaryCompletion":1317,"completion":1318,"start":1319,"enrollment":509,"conditions":1320,"interventions":1322},"NCT06003270","Biological Effects of Quercetin in COPD Phase II",[44],"2025-02-15","2025-07-31","2023-11-01",[22,584,1321],"Chronic Bronchitis With Airway Obstruction",[1305,1323],"Quercetin 500 MG",{"trials":1325,"activeCount":53},[],{"trials":1327,"activeCount":53},[],{"trials":1329,"activeCount":53},[],{"intervention":1323,"totalTrials":12,"cells":1331},{"EARLY_PHASE1":1332,"PHASE1":1334,"PHASE2":1336,"PHASE3":1342,"PHASE4":1344,"NA":1346},{"trials":1333,"activeCount":53},[],{"trials":1335,"activeCount":53},[],{"trials":1337,"activeCount":53},[1338],{"nctId":1314,"briefTitle":1315,"status":89,"phases":1339,"primaryCompletion":1317,"completion":1318,"start":1319,"enrollment":509,"conditions":1340,"interventions":1341},[44],[22,584,1321],[1305,1323],{"trials":1343,"activeCount":53},[],{"trials":1345,"activeCount":53},[],{"trials":1347,"activeCount":53},[],{"intervention":1349,"totalTrials":1350,"cells":1351},"Clavulanic Acid",3,{"EARLY_PHASE1":1352,"PHASE1":1354,"PHASE2":1390,"PHASE3":1392,"PHASE4":1394,"NA":1396},{"trials":1353,"activeCount":53},[],{"trials":1355,"activeCount":53},[1356,1369,1380],{"nctId":1357,"briefTitle":1358,"status":153,"phases":1359,"primaryCompletion":1360,"completion":1360,"start":1361,"enrollment":803,"conditions":1362,"interventions":1366},"NCT02563769","Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study",[43],"2018-05-25","2016-10-24",[64,1363,1364,1365],"Cocaine Addiction","Cocaine Abuse","Cocaine-Related Disorders",[1367,1368],"Clavulanic acid","Intravenous cocaine",{"nctId":1370,"briefTitle":1371,"status":153,"phases":1372,"primaryCompletion":1373,"completion":1373,"start":1374,"enrollment":1375,"conditions":1376,"interventions":1379},"NCT03986762","Open Label Pharmaco- Magnetic Resonance Spectrography (MRS) Study of Clavulanic Acid",[43],"2019-12-20","2019-03-12",9,[1377,1378,1365],"Cocaine Dependence, in Remission","Cocaine Abuse, in Remission",[1349],{"nctId":1381,"briefTitle":1382,"status":153,"phases":1383,"primaryCompletion":1384,"completion":1385,"start":1386,"enrollment":1387,"conditions":1388,"interventions":1389},"NCT04411914","Pharmaco-Magnetic Resonance Spectroscopy (MRS) Study of Clavulanic Acid",[43],"2021-11-23","2022-03-31","2020-09-01",13,[64],[1349],{"trials":1391,"activeCount":53},[],{"trials":1393,"activeCount":53},[],{"trials":1395,"activeCount":53},[],{"trials":1397,"activeCount":53},[],{"intervention":1368,"totalTrials":12,"cells":1399},{"EARLY_PHASE1":1400,"PHASE1":1402,"PHASE2":1408,"PHASE3":1410,"PHASE4":1412,"NA":1414},{"trials":1401,"activeCount":53},[],{"trials":1403,"activeCount":53},[1404],{"nctId":1357,"briefTitle":1358,"status":153,"phases":1405,"primaryCompletion":1360,"completion":1360,"start":1361,"enrollment":803,"conditions":1406,"interventions":1407},[43],[64,1363,1364,1365],[1367,1368],{"trials":1409,"activeCount":53},[],{"trials":1411,"activeCount":53},[],{"trials":1413,"activeCount":53},[],{"trials":1415,"activeCount":53},[],{"intervention":1417,"totalTrials":12,"cells":1418},"Ceftolozane-Tazobactam",{"EARLY_PHASE1":1419,"PHASE1":1421,"PHASE2":1423,"PHASE3":1425,"PHASE4":1427,"NA":1429},{"trials":1420,"activeCount":53},[],{"trials":1422,"activeCount":53},[],{"trials":1424,"activeCount":53},[],{"trials":1426,"activeCount":53},[],{"trials":1428,"activeCount":53},[],{"trials":1430,"activeCount":53},[1431],{"nctId":1432,"briefTitle":1433,"status":153,"phases":1434,"primaryCompletion":1435,"completion":1435,"start":1436,"enrollment":1437,"conditions":1438,"interventions":1441},"NCT03510351","Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections",[],"2018-02-28","2017-02-01",200,[1439,1440],"Pseudomonas Infections","Pseudomonas Aeruginosa",[1417],{"intervention":1443,"totalTrials":12,"cells":1444},"Nicotine polacrilex",{"EARLY_PHASE1":1445,"PHASE1":1447,"PHASE2":1449,"PHASE3":1451,"PHASE4":1453,"NA":1455},{"trials":1446,"activeCount":53},[],{"trials":1448,"activeCount":53},[],{"trials":1450,"activeCount":53},[],{"trials":1452,"activeCount":53},[],{"trials":1454,"activeCount":53},[],{"trials":1456,"activeCount":53},[1457],{"nctId":1458,"briefTitle":1459,"status":153,"phases":1460,"primaryCompletion":1461,"completion":1461,"start":155,"enrollment":1462,"conditions":1463,"interventions":1466},"NCT02602288","Babies Living Safe and Smokefree",[47],"2019-10-23",396,[1464,1465],"Second Hand Tobacco Smoke","Nicotine Dependence",[1443],{"intervention":1468,"totalTrials":12,"cells":1469},"Botulinum toxin A",{"EARLY_PHASE1":1470,"PHASE1":1472,"PHASE2":1474,"PHASE3":1476,"PHASE4":1478,"NA":1480},{"trials":1471,"activeCount":53},[],{"trials":1473,"activeCount":53},[],{"trials":1475,"activeCount":53},[],{"trials":1477,"activeCount":53},[],{"trials":1479,"activeCount":53},[],{"trials":1481,"activeCount":53},[1482],{"nctId":1483,"briefTitle":1484,"status":153,"phases":1485,"primaryCompletion":1129,"completion":1129,"start":1486,"enrollment":438,"conditions":1487,"interventions":1488},"NCT00372970","Placebo Controlled Trial of Botulinum Toxin for Gastroparesis",[47],"2003-07",[34],[1468],{"intervention":1490,"totalTrials":12,"cells":1491},"Desipramine",{"EARLY_PHASE1":1492,"PHASE1":1494,"PHASE2":1496,"PHASE3":1498,"PHASE4":1500,"NA":1502},{"trials":1493,"activeCount":53},[],{"trials":1495,"activeCount":53},[],{"trials":1497,"activeCount":53},[],{"trials":1499,"activeCount":53},[],{"trials":1501,"activeCount":53},[],{"trials":1503,"activeCount":53},[1504],{"nctId":1505,"briefTitle":1506,"status":101,"phases":1507,"primaryCompletion":1508,"completion":1508,"start":249,"enrollment":803,"conditions":1509,"interventions":1511},"NCT00220844","Tricyclic Antidepressants (TCAs) on Gastric Emptying",[47],"2014-06",[1510],"Dyspepsia",[1490,1512],"Amitriptyline",{"intervention":1512,"totalTrials":12,"cells":1514},{"EARLY_PHASE1":1515,"PHASE1":1517,"PHASE2":1519,"PHASE3":1521,"PHASE4":1523,"NA":1525},{"trials":1516,"activeCount":53},[],{"trials":1518,"activeCount":53},[],{"trials":1520,"activeCount":53},[],{"trials":1522,"activeCount":53},[],{"trials":1524,"activeCount":53},[],{"trials":1526,"activeCount":53},[1527],{"nctId":1505,"briefTitle":1506,"status":101,"phases":1528,"primaryCompletion":1508,"completion":1508,"start":249,"enrollment":803,"conditions":1529,"interventions":1530},[47],[1510],[1490,1512],{"intervention":1532,"totalTrials":12,"cells":1533},"Ceftazidime-avibactam",{"EARLY_PHASE1":1534,"PHASE1":1536,"PHASE2":1538,"PHASE3":1540,"PHASE4":1542,"NA":1544},{"trials":1535,"activeCount":53},[],{"trials":1537,"activeCount":53},[],{"trials":1539,"activeCount":53},[],{"trials":1541,"activeCount":53},[],{"trials":1543,"activeCount":53},[],{"trials":1545,"activeCount":53},[1546],{"nctId":1547,"briefTitle":1548,"status":89,"phases":1549,"primaryCompletion":1550,"completion":1551,"start":1552,"enrollment":803,"conditions":1553,"interventions":1557},"NCT03243864","Study of Ceftazidime-Avibactam Blood Concentrations in Intensive Care Unit Patients With Renal Failure Requiring Continuous Dialysis",[],"2020-03-21","2020-10-21","2017-03-13",[1554,1555,1556],"Renal Failure","Bacterial Infections","Critical Illness",[1532],{"intervention":1559,"totalTrials":12,"cells":1560},"Experimental Sequence ABC",{"EARLY_PHASE1":1561,"PHASE1":1563,"PHASE2":1565,"PHASE3":1567,"PHASE4":1569,"NA":1571},{"trials":1562,"activeCount":53},[],{"trials":1564,"activeCount":53},[],{"trials":1566,"activeCount":53},[],{"trials":1568,"activeCount":53},[],{"trials":1570,"activeCount":53},[],{"trials":1572,"activeCount":53},[1573],{"nctId":1574,"briefTitle":1575,"status":153,"phases":1576,"primaryCompletion":555,"completion":1577,"start":530,"enrollment":1578,"conditions":1579,"interventions":1581},"NCT00685477","Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying",[47],"2009-07",60,[1580],"Healthy",[1559,1582,1583,1584,1585,1586],"Experimental Sequence ACB","Experimental Sequence BAC","Experimental Sequence BCA","Experimental Sequence CAB","Experimental Sequence CBA",{"intervention":1582,"totalTrials":12,"cells":1588},{"EARLY_PHASE1":1589,"PHASE1":1591,"PHASE2":1593,"PHASE3":1595,"PHASE4":1597,"NA":1599},{"trials":1590,"activeCount":53},[],{"trials":1592,"activeCount":53},[],{"trials":1594,"activeCount":53},[],{"trials":1596,"activeCount":53},[],{"trials":1598,"activeCount":53},[],{"trials":1600,"activeCount":53},[1601],{"nctId":1574,"briefTitle":1575,"status":153,"phases":1602,"primaryCompletion":555,"completion":1577,"start":530,"enrollment":1578,"conditions":1603,"interventions":1604},[47],[1580],[1559,1582,1583,1584,1585,1586],{"intervention":1583,"totalTrials":12,"cells":1606},{"EARLY_PHASE1":1607,"PHASE1":1609,"PHASE2":1611,"PHASE3":1613,"PHASE4":1615,"NA":1617},{"trials":1608,"activeCount":53},[],{"trials":1610,"activeCount":53},[],{"trials":1612,"activeCount":53},[],{"trials":1614,"activeCount":53},[],{"trials":1616,"activeCount":53},[],{"trials":1618,"activeCount":53},[1619],{"nctId":1574,"briefTitle":1575,"status":153,"phases":1620,"primaryCompletion":555,"completion":1577,"start":530,"enrollment":1578,"conditions":1621,"interventions":1622},[47],[1580],[1559,1582,1583,1584,1585,1586],{"intervention":1584,"totalTrials":12,"cells":1624},{"EARLY_PHASE1":1625,"PHASE1":1627,"PHASE2":1629,"PHASE3":1631,"PHASE4":1633,"NA":1635},{"trials":1626,"activeCount":53},[],{"trials":1628,"activeCount":53},[],{"trials":1630,"activeCount":53},[],{"trials":1632,"activeCount":53},[],{"trials":1634,"activeCount":53},[],{"trials":1636,"activeCount":53},[1637],{"nctId":1574,"briefTitle":1575,"status":153,"phases":1638,"primaryCompletion":555,"completion":1577,"start":530,"enrollment":1578,"conditions":1639,"interventions":1640},[47],[1580],[1559,1582,1583,1584,1585,1586],{"intervention":1585,"totalTrials":12,"cells":1642},{"EARLY_PHASE1":1643,"PHASE1":1645,"PHASE2":1647,"PHASE3":1649,"PHASE4":1651,"NA":1653},{"trials":1644,"activeCount":53},[],{"trials":1646,"activeCount":53},[],{"trials":1648,"activeCount":53},[],{"trials":1650,"activeCount":53},[],{"trials":1652,"activeCount":53},[],{"trials":1654,"activeCount":53},[1655],{"nctId":1574,"briefTitle":1575,"status":153,"phases":1656,"primaryCompletion":555,"completion":1577,"start":530,"enrollment":1578,"conditions":1657,"interventions":1658},[47],[1580],[1559,1582,1583,1584,1585,1586],{"intervention":1586,"totalTrials":12,"cells":1660},{"EARLY_PHASE1":1661,"PHASE1":1663,"PHASE2":1665,"PHASE3":1667,"PHASE4":1669,"NA":1671},{"trials":1662,"activeCount":53},[],{"trials":1664,"activeCount":53},[],{"trials":1666,"activeCount":53},[],{"trials":1668,"activeCount":53},[],{"trials":1670,"activeCount":53},[],{"trials":1672,"activeCount":53},[1673],{"nctId":1574,"briefTitle":1575,"status":153,"phases":1674,"primaryCompletion":555,"completion":1577,"start":530,"enrollment":1578,"conditions":1675,"interventions":1676},[47],[1580],[1559,1582,1583,1584,1585,1586]]